Remedium Bio is a gene therapy company focused on the development of treatments for large unmet clinical needs.
To enable this, we developed a revolutionary gene therapy platform technology, which enables safe, effective, and durable delivery of therapeutic genes while allowing for simple post-treatment dose adjustment.
The Prometheus™ adjustable gene therapy platform is able to safely and durably replace multi-injection subcutaneously administered biologics, with a single treatment, at a fraction of the cost, and without genetic integration.
Our lead product is a disease-modifying treatment for Osteoarthritis that is based on the only clinically validated chondro-regenerative mechanism.
Remedium’s pipeline includes gene therapy treatments in the fields of Weight Loss, Type 2 Diabetes, and Stroke.
Remedium has developed the only dose-adjustable gene therapy platform: Prometheus™.
The technology utilizes a highly biocompatible, non-viral delivery vector, for targeted, durable, and adjustable gene expression.
Prometheus™ enables replacement of virtually any subcutaneously administered protein as a single injection, adjustable dose gene therapy – at a fraction of the current treatment cost and with improved pharmacokinetics.
We are honored to have been selected amongst the finalists for the Boehringer Ingelheim Innovation Day and looking forward to presenting Remedium Bio and our Prometheus™ dose-adjustable gene therapy platform technology on Oct 26th.
#genetherapy #biotechnology #innovation
https://lnkd.in/e5ShXu53